Axial giant cell tumor - current standard of practice

Navaneeth Kamath; Jasmine Agarwal; Ashish Gulia

doi:10.1016/j.jcot.2019.09.025

Axial giant cell tumor - current standard of practice

J Clin Orthop Trauma. 2019 Nov-Dec;10(6):1027-1032. doi: 10.1016/j.jcot.2019.09.025. Epub 2019 Oct 9.

Authors

Navaneeth Kamath¹, Jasmine Agarwal¹, Ashish Gulia¹

Affiliation

¹ Orthopedic Oncology Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabhi National Institute, Mumbai, India.

Abstract

Giant cell tumors of bone are relatively rare in the axial skeleton, accounting for approximately 6.7% of all cases. Due to their anatomical complexity, difficult access and proximity to vital neurovascular structures, management of these tumors poses a huge challenge on the treating surgeon. Several data series reported on axial GCTB involve short series of limited cases with varied methods used in their local control due to which, proper guidelines are unavailable for the management of such difficult cases. Though the present data support the use of denosumab for effective management of these lesions but there is varied consensus on dosage and duration of treatment. This review article summarizes the basic features and treatment modalities related to axial GCTB stressing on multidisciplinary approach to achieve optimum outcomes.

Keywords: Angioembolization; Axial; Curettage; Denosumab; Giant cell tumor; Management.

Publication types

Review